MUST Research Group

The MUST trial is a randomized controlled clinical trial that compares two treatments for patients suffering from vision-threatening non-infectious uveitis, which includes conditions like intermediate uveitis, posterior uveitis, and panuveitis. One treatment involves local therapy using a fluocinolone acetonide intraocular implant in the affected eyes, while the other is standard therapy consisting of systemic corticosteroid therapy, which may be supplemented by corticosteroid-sparing potent immunomodulator therapy when necessary.

From 2011, the year the MUST trial first published its findings, to 2017, the American Uveitis Society identified 76 publications as the top papers of the year for educational purposes. Remarkably, the MUST Trial and its Follow-up Study have contributed 14 of these notable papers, accounting for 18.4% of the selected works in the field of medical research on uveitis.